Search

Aflibercept, bevacizumab or ranibizumab for DMO

This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...

Intravitreal bevacizumab vs. triamcinolone in patients with DMO at the time of cataract surgery

This prospective, single masked randomised control trial (RCT) compared visual and anatomical outcomes when either intravitreal bevacizumab (BVB) or triamcinolone (TA) was administered at the time of cataract surgery and at subsequent review, if required, in patients with diabetic macula...

OCT angiography sign after whiplash

Berlin’s oedema is a rare condition following blunt ocular injury and a rare finding after whiplash injury. This case describes a 48-year-old male who suffered a seventh vertebrae fracture from a traffic accident. Two days later, decreased left eye visual...

Acetazolamide and CMO

The authors set out to analyse the effect of acetazolamide therapy on inflammatory cystoid macular oedema (CMO) as defined by change in central macular subfield thickness (CST), as well as its effect on visual acuity. A retrospective chart review was...

Subthreshold micropulse laser in BRVO

The purpose of this retrospective, consecutive, single-centre, non-randomised, and case-control study was to verify the therapeutic effects and safety of oedema (from branch retinal vein occlusion (BRVO)) recurrence suppression effect using 577-nm subthreshold micropulse laser photocoagulation (SMLP) in combination with...

IVTA for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis

This meta-analysis aimed to compare the safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular oedema (DME) and macular oedema (ME) secondary to retinal vein occlusion (RVO). A systematic literature search for randomised controlled trials...

Intravitreal dexamethasone implant for recurrent CMO secondary to IGS

In this prospective study the authors present the data obtained on the efficacy and safety of the dexamethasone implant (0.7 mg) in the treatment of recurrent cystoid macular oedema (PCME) due to Irvine–Gass syndrome in patients with uncomplicated pseudophakia (off-label...

Effect of single intravitreal injection of bevacizumab on contrast sensitivity in patients with central retinal vein occlusion

Central retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy. There are many studies reporting the efficacy of intravitreal anti-VEGF injections for macular oedema secondary to retinal vein occlusions. This paper looks at the contrast...

Advanced vestibular Schwannoma case report

Vestibular Schwannoma is a benign, slow growing tumour which usually presents with unilateral hearing loss. It causes symptoms and findings on ophthalmic examination when the diagnosis is delayed. Ophthalmic findings may be related to the effect of the expanding mass...